SOHO State of the Art Updates and Next Questions | The Evolving Landscape of Prognostic Models in Chronic Lymphocytic Leukemia.

Abstract

The advent of targeted therapies has profoundly altered the prognostic landscape of chronic lymphocytic leukemia (CLL), demanding a reassessment of established predictive models. Initial frameworks, such as the CLL International Prognostic Index (CLL-IPI), primarily relied on clinical and genetic parameters. However, the growing clinical utility of targeted agents highlights the ongoing need to refine these prognostic tools. Although the CLL-IPI remains a valuable metric for progression-free survival (PFS), its capacity to accurately predict overall survival (OS) has been attenuated by the evolution of therapeutic approaches. Novel prognostic models hold promise by leveraging advanced technologies, sophisticated statistical methods, and computational analytics to improve risk stratification. These innovations address the inherent limitations of conventional models, enabling more precise and individualized prognostic assessments. To maintain clinical utility, however, these models must continuously adapt alongside the rapidly advancing therapeutic landscape of CLL. Optimizing patient outcomes requires a fundamental paradigm shift that integrates a broader and more dynamic array of patient-specific data into prognostic evaluations.